<DOC>
	<DOC>NCT01656512</DOC>
	<brief_summary>Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for one fourth of all childhood cancers &amp; 74 % of childhood leukemia. Based upon drug registry data, children prescribed more than three courses of systemic glucocorticoids yearly faced a 20% increase in age-adjusted fracture rates. Rapid recovery occurred once glucocorticoids were discontinued, and fracture rates returned to expected for age by 1 year after treatment (Journal Of Clinical Endocrinology &amp; Metabolism 2009). The investigators will study the role of bisphosphonates in the prevention of secondary osteoporosis in children &amp; adolescents treated for ALL in the Children's Cancer Hospital -Egypt.</brief_summary>
	<brief_title>Zometa Study in Pediatric Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Age above 5 &amp; below 18 years at the time of diagnosis. Newly diagnosed ALL patients. Not previously treated, previous steroid intake not more than 72 hours. Treated according to St Judy study XV protocol. Previous steroid intake more than 72 hours. Less than 5 years</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ALL</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>